Intellipharmaceutics Announces Third Quarter 2022 Results

Rhea-AI Summary

Intellipharmaceutics International Inc. (OTCQB:IPCIF) reported its operational results for the three and nine months ending August 31, 2022. The company achieved revenues of $19,068, attributed to a license agreement with Taro Pharmaceuticals, compared to $Nil in Q3 2021. Net loss decreased to $296,043 per share, from $1,264,305 in the previous year. R&D expenses declined to $626,069, while SG&A expenses fell to $(292,296). As of the reporting date, cash balance stood at $79,649. The company highlighted the need for additional funding for continued R&D and product commercialization.

Positive

• Achieved revenue of $19,068 from license agreement with Taro Pharmaceuticals.
• Net loss reduced to $296,043 from $1,264,305 year-over-year, indicating improved financial performance.
• Decrease in R&D and SG&A expenses, reflecting cost management efforts.

Negative

• No revenue from generic Focalin XR® due to increased gross-to-net deductions.
• Cash balance of $79,649 raises concerns about liquidity and funding for ongoing operations.
• Termination of exclusive licenses with Tris Pharma may hinder product commercialization opportunities.

TORONTO, ON / ACCESSWIRE / October 14, 2022 / - Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2022. All dollar amounts referenced herein are in United States dollars unless otherwise noted.

• In August 2022 the Company announced that it has entered into a license and supply agreement with Taro Pharmaceuticals Inc. ("Taro"), by which the Company has granted Taro an exclusive license to market, sell and distribute in Canada, Desvenlafaxine Extended-release Tablets in the 50 mg and 100 mg strengths (the "licensed product") approved for sale in the Canadian market by the Pharmaceutical Drugs Directory (PDD) of Health Canada.
• In February 2022 the Company received marketing approval for the Canadian market from Health Canada (notice of compliance) for generic Pristiq (desvenlafaxine succinate extended-release tablets) in the 50 and 100 mg strengths.
• In November 2021 the Company received final FDA approval for its Dexmethylphenidate Extended-release Capsules in the 5 mg, 10 mg, 30 mg and 40 mg strengths. The 15 mg and 30 mg strengths were initially approved and commercialized by Par Pharmaceutical Inc. (Par) in November 2013; the additional strengths launched to date were approved in a Par abbreviated new drug application.

Results of Operations

The Company recorded net loss for the three months ended August 31, 2021 of $296,043 or $0.01 per common share, compared with a net loss of $1,264,305 or $0.04 per common share for the three months ended August 31, 2021.

The Company recorded revenues of $19,068 for the three months ended August 31, 2022 versus $Nil for the three months ended August 31, 2021. Such revenues consisted primarily of up-front payment from a license and supply agreement for the three months ended August 31, 2022. there was no revenue from generic Focalin XR^® for the three months ended August 31, 2022, primarily due to a marked increase in gross-to-net deductions such as wholesaler rebates, chargebacks and pricing adjustments which continues to date.

Expenditures for R&D were $626,069 for the three months ended August 31, 2022 in comparison to $723,224 for the three months ended August 31, 2021, resulting in a decrease of $101,633 compared to the three months ended August 31, 2021. During both periods there was allocation of losses on royalty payments for generic Focalin XR^®.

Selling, general and administrative expenses were $(292,296) for the three months ended August 31, 2022 in comparison to $295,217 for the three months ended August 31, 2021, resulting in a decrease of $587,513. The decrease is mainly due to a significant decrease in administrative costs, and a decrease in wages.

As of August 31, 2022, our cash balance was $79,649. We currently expect to meet our short-term cash requirements from potential revenues for approved generic products or other collaborations, other available financing and by cost savings resulting from reduced R&D activities and staffing levels, as well as quarterly profit share from Par. Effective May 5, 2021 our exclusive license agreements with Tris Pharma, Inc. for generic Seroquel XR^®, generic Pristiq^® and generic Effexor XR^®were mutually terminated. Products were never supplied nor distributed under the licenses. Termination of the exclusive agreements may provide opportunity for the Company to explore options of supplying the products to multiple sources on non-exclusive bases. However, there can be no assurance that the products previously licensed to Tris Pharma will be successfully commercialized and produce significant revenues for us. We will need to obtain additional funding to, among other things, further product commercialization activities and development of our product candidates. Potential sources of capital may include, if conditions permit, equity and/or debt financing, payments from licensing and/or development agreements and/or new strategic partnership agreements. There can be no assurance that we will be able to enter into additional collaborations or, if we do, that such arrangements will be commercially viable or beneficial. The Company has funded its business activities principally through the issuance of securities, loans from related parties (see "Related Party Transactions" for more information related to the terms of such loans and applicable maturities) and funds from development agreements. There is no certainty that such funding will be available going forward or, if it is, whether it will be sufficient to meet our needs. Our future operations are highly dependent upon our ability to source additional funding to support advancing our product candidate pipeline through continued R&D activities and to expand our operations. Our ultimate success will depend on whether our product candidates are approved by the FDA, Health Canada, or the regulatory authorities of other countries in which our products are proposed to be sold and whether we are able to successfully market our approved products. We cannot be certain that we will receive such regulatory approval for any of our current or future product candidates, that we will reach the level of revenues necessary to achieve and sustain profitability, or that we will secure other capital sources on terms or in amounts sufficient to meet our needs, or at all.

About Intellipharmaceutics

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company's patented Hypermatrix™ technology is a multidimensional controlled-release drug delivery platform that can be applied to a wide range of existing and new pharmaceuticals. Intellipharmaceutics has developed several drug delivery systems based on this technology platform, with a pipeline of products (some of which have received FDA approval) in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Company's Oxycodone ER based on its proprietary nPODDDS™ novel Point Of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin™ XR (pregabalin extended-release capsules).

Cautionary Statement Regarding Forward-Looking Information

Certain statements in this document constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements include, without limitation, statements expressed or implied regarding our expectations , plans, goals and milestones, status of developments or expenditures relating to our business, plans to fund our current activities, and statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future sales, revenues and profitability, projected costs and market penetration and risks or uncertainties arising from the delisting of our shares from Nasdaq and our ability to comply with OTCQB and TSX requirements. In some cases, you can identify forward-looking statements by terminology such as "appear", "unlikely", "target", "may", "will", "should", "expects", "plans", "plans to", "anticipates", "believes", "estimates", "predicts", "confident", "prospects", "potential", "continue", "intends", "look forward", "could", "would", "projected", "goals" ,"set to", "seeking" or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of our forward-looking statements. You should not place undue reliance on our forward-looking statements, which are subject to a multitude of known and unknown risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those stated in or implied by the forward-looking statements. Risks, uncertainties and other factors that could affect our actual results include, but are not limited to, , the effects of general economic conditions, securing and maintaining corporate alliances, our estimates regarding our capital requirements, and the effect of capital market conditions and other factors, including the current status of our product development programs, capital availability, the estimated proceeds (and the expected use of any proceeds) we may receive from any offering of our securities, the potential dilutive effects of any future financing, potential liability from and costs of defending pending or future litigation, risks associated with the novel coronavirus (COVID-19) including its impact on our business and operations, our programs regarding research, development and commercialization of our product candidates, the timing of such programs, the timing, costs and uncertainties regarding obtaining regulatory approvals to market our product candidates and the difficulty in predicting the timing and results of any product launches, the timing and amount of profit-share payments from our commercial partners, and the timing and amount of any available investment tax credits, the actual or perceived benefits to users of our drug delivery technologies, products and product candidates as compared to others, our ability to establish and maintain valid and enforceable intellectual property rights in our drug delivery technologies, products and product candidates, the scope of protection provided by intellectual property rights for our drug delivery technologies, products and product candidates, recent and future legal developments in the United States and elsewhere that could make it more difficult and costly for us to obtain regulatory approvals for our product candidates and negatively affect the prices we may charge, increased public awareness and government scrutiny of the problems associated with the potential for abuse of opioid based medications, pursuing growth through international operations could strain our resources, our limited manufacturing, sales, marketing and distribution capability and our reliance on third parties for such, the actual size of the potential markets for any of our products and product candidates compared to our market estimates, our selection and licensing of products and product candidates, our ability to attract distributors and/or commercial partners with the ability to fund patent litigation and with acceptable product development, regulatory and commercialization expertise and the benefits to be derived from such collaborative efforts, sources of revenues and anticipated revenues, including contributions from distributors and commercial partners, product sales, license agreements and other collaborative efforts for the development and commercialization of product candidates, our ability to create an effective direct sales and marketing infrastructure for products we elect to market and sell directly, the rate and degree of market acceptance of our products, delays in product approvals that may be caused by changing regulatory requirements, the difficulty in predicting the timing of regulatory approval and launch of competitive products, the difficulty in predicting the impact of competitive products on sales volume, pricing, rebates and other allowances, the number of competitive product entries, and the nature and extent of any aggressive pricing and rebate activities that may follow, the inability to forecast wholesaler demand and/or wholesaler buying patterns, seasonal fluctuations in the number of prescriptions written for our generic Focalin XR® capsules which may produce substantial fluctuations in revenue, the timing and amount of insurance reimbursement regarding our products, changes in laws and regulations affecting the conditions required by the FDA for approval, testing and labeling of drugs including abuse or overdose deterrent properties, and changes affecting how opioids are regulated and prescribed by physicians, changes in laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products, the effect of recent changes in U.S. federal income tax laws, including but not limited to, limitations on the deductibility of business interest, limitations on the use of net operating losses and application of the base erosion minimum tax, on our U.S. corporate income tax burden, the success and pricing of other competing therapies that may become available, our ability to retain and hire qualified employees, the availability and pricing of third-party sourced products and materials, challenges related to the development, commercialization, technology transfer, scale-up, and/or process validation of manufacturing processes for our products or product candidates, the manufacturing capacity of third-party manufacturers that we may use for our products, potential product liability risks, the recoverability of the cost of any pre-launch inventory, should a planned product launch encounter a denial or delay of approval by regulatory bodies, a delay in commercialization, or other potential issues, the successful compliance with FDA, Health Canada and other governmental regulations applicable to us and our third party manufacturers' facilities, products and/or businesses, our reliance on commercial partners, and any future commercial partners, to market and commercialize our products and, if approved, our product candidates, difficulties, delays or changes in the FDA approval process or test criteria for ANDAs and NDAs, challenges in securing final FDA approval for our product candidates, including our oxycodone hydrochloride extended release tablets product candidate, in particular, if a patent infringement suit is filed against us with respect to any particular product candidates (such as in the case of Oxycodone ER), which could delay the FDA's final approval of such product candidates, healthcare reform measures that could hinder or prevent the commercial success of our products and product candidates, the risk that the FDA may not approve requested product labeling for our product candidate(s) having abuse-deterrent properties and targeting common forms of abuse (oral, intra-nasal and intravenous), risks associated with cyber-security and the potential for vulnerability of our digital information or the digital information of a current and/or future drug development or commercialization partner of ours, and risks arising from the ability and willingness of our third-party commercialization partners to provide documentation that may be required to support information on revenues earned by us from those commercialization partners. Additional risks and uncertainties relating to us and our business can be found in the "Risk Factors" section of our latest annual information form, our latest Form 20-F, and our latest Form F-1 and F-3 registration statements (including any documents forming a part thereof or incorporated by reference therein), as amended, as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada and the U.S., which are available on www.sedar.com and www.sec.gov. The forward-looking statements reflect our current views with respect to future events and are based on what we believe are reasonable assumptions as of the date of this document and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Trademarks used herein are the property of their respective holders.

Unless the context otherwise requires, all references (i) to "we," "us," "our," "Intellipharmaceutics," and the "Company" refer to Intellipharmaceutics International Inc. and its subsidiaries and (ii) in this document to share amounts, per share data, share prices, exercise prices and conversion rates have been adjusted to reflect the effect of the 1-for-10 reverse split which became effective on each of Nasdaq and TSX at the open of market on September 14, 2018. The common shares of the Company are currently traded on the OTCQB and the TSX.

Nothing contained in this document should be construed to imply that the results discussed herein will necessarily continue into the future or that any conclusion reached herein will necessarily be indicative of our actual operating results.

The condensed unaudited interim consolidated financial statements, accompanying notes to the condensed unaudited interim consolidated financial statements, and Management Discussion and Analysis for the three and nine months ended August 31, 2022 will be accessible on Intellipharmaceutics' website at www.intellipharmaceutics.com and will be available on SEDAR and EDGAR.

Summary financial tables are provided below.

Intellipharmaceutics International Inc.
Consolidated balance sheets
As at
(Stated in U.S. dollars)

		August 31,				November 30,
		2022				2021
			$				$
Assets
Current
Cash			79,649				771,945
Investment tax credits			268,179				268,179
Prepaid expenses, sundry and other assets			206,997				62,192
			554,825				1,102,316
Property and equipment, net			839,674				994,109
Right-of-use asset			42,523				-
			1,437,022				2,096,425
Liabilities
Current
Accounts payable			4,259,134				3,779,550
Accrued liabilities			2,458,853				2,272,610
Employee costs payable			2,847,509				2,263,944
Operating lease liability			43,398				-
Income tax payable			18,178				18,178
Promissory notes payable			162,004				165,878
Convertible debentures			1,800,000				1,751,483
			11,589,076				10,251,643
Shareholders' deficiency
Capital stock
Authorized
Unlimited common shares without par value
Unlimited preference shares
Issued and outstanding
33,092,665 common shares			49,175,630				49,175,630
(November 30, 2020 - 23,678,105)
Additional paid-in capital			44,647,269				44,626,436
Accumulated other comprehensive income			284,421				284,421
Accumulated deficit			(104,259,374	)			(102,241,705	)
			(10,152,054	)			(8,155,218	)
Contingencies
			1,437,022				2,096,425

Intellipharmaceutics International Inc.
Condensed unaudited interim consolidated statements of operations and comprehensive income (loss)
For the three and nine months ended August 31, 2022 and 2021
(Stated in U.S. dollars)

		Three months ended								Nine months ended
		August 31, 2022				August 31, 2021				August 31, 2022				August 31, 2021
			$				$				$				$
Revenue
Licensing			-				-				16,978				-
Up-front fees			19,068				-				19,068				-
			19,068				-				36,046				-
Expenses
Research and development			626,069				723,224				2,060,477				1,658,961
Selling, general and administrative			(292,296	)			295,217				212,063				920,482
Depreciation			51,478				65,381				154,435				196,144
			385,251				1,083,822				2,426,975				2,775,587
Loss from operations			(366,183	)			(1,083,822	)			(2,390,929	)			(2,775,587	)
Net foreign exchange gain (loss)			123,171				31,967				100,320				(45,982	)
Interest income			-				-				-				-
Interest expense			(53,031	)			(212,450	)			(227,060	)			(367,486	)
Loss on disposal of asset			-				-				500,000				-
Net (loss) income and comprehensive (loss) income			(296,043	)			(1,264,305	)			(2,017,669	)			(3,189,055	)
Net (loss) income per common share, basic and diluted			(0.01	)			(0.04	)			(0.07	)			(0.11	)
Weighted average number of common
shares outstanding basic and diluted			33,092,665				33,092,665				28,213,586				28,213,586

Intellipharmaceutics International Inc.
Condensed unaudited interim consolidated statements of cash flows
For the three and nine months ended August 31, 2022 and 2021
(Stated in U.S. dollars)

		Three months ended								Nine months ended
		August 31, 2022				August 31, 2021				August 31, 2022				August 31, 2021
			$				$				$				$
Net income (loss )			(296,043	)			(1,264,305	)			(2,017,669	)			(3,189,055	)
Items not affecting cash
Depreciation			51,478				65,381				154,435				196,144
Stock-based compensation			-				-				-				11,985
Accreted interest on convertible debenture			-				157,844				69,351				207,726
Gain on disposal of asset			-				-				(500,000	)			-
Non-cash lease expense			39,620				37,738				(42,523	)			100,391
Unrealized foreign exchange (gain) loss			(5,691	)			(10,002	)			(3,879	)			3,681
Change in non-cash operating assets & liabilities
Trade and other receivables			-				119,255				-				566,384
Investment tax credits			-				-				-				-
Inventory			-				8,689				-				8,689
Prepaid expenses, sundry and other assets			60,316				(69,040	)			(144,805	)			(35,102	)
Accounts payable, accrued liabilities and employee costs payable			(103,039	)			(367,005	)			1,249,396				116,516
Operating lease liability			(39,787	)			(40,988	)			43,398				(112,935	)
Cash flows used in operating activities			(293,146	)			(1,362,433	)			(1,192,296	)			(2,125,576	)
Financing activities
Proceeds from private placement financing			-				-				-				3,069,448
Cost related to private placement financing			-				-				-				(38,220	)
Cash flows provided from financing activities			-				-				-				3,031,228
Investing activity
Purchase of property and equipment			-				-				-				-
Sale of property and equipment			-				-				500,000				-
Cash flows provided from investing activities			-				-				500,000				-
(Decrease) increase in cash			(293,146	)			(1,362,433	)			(692,296	)			905,652
Cash, beginning of period			372,795				2,470,131				771,945				202,046
Cash, end of period			79,649				1,107,698				79,649				1,107,698
Supplemental cash flow information
Interest paid			-				-				-				-
Taxes paid			-				-				-				-

CONTACT INFORMATION

Company Contact:
Intellipharmaceutics International Inc.
Isa Odidi
Chief Executive Officer
416.798.3001 ext. 102
investors@intellipharmaceutics.com

SOURCE: Intellipharmaceutics International Inc.

View source version on accesswire.com:
https://www.accesswire.com/720503/Intellipharmaceutics-Announces-Third-Quarter-2022-Results

FAQ

What were Intellipharmaceutics' key financial results for Q3 2022?

Intellipharmaceutics reported revenues of $19,068 and a net loss of $296,043 for Q3 2022.

How did Intellipharmaceutics' R&D expenses change in Q3 2022?

R&D expenses decreased to $626,069 in Q3 2022 from $723,224 in Q3 2021.

What is the significance of the licensing agreement with Taro Pharmaceuticals for IPCIF?

The licensing agreement with Taro Pharmaceuticals brought in $19,068 in revenue, marking an important development for IPCIF.

What challenges does Intellipharmaceutics face in terms of funding?

Intellipharmaceutics needs additional funding to support R&D activities and product commercialization, with a current cash balance of $79,649.

What impact did the termination of exclusive licenses with Tris Pharma have on Intellipharmaceutics?

The termination may limit commercialization of certain products, though it opens potential for non-exclusive supply agreements.